Skip navigation
  • 中文
  • English

DSpace CRIS

  • DSpace logo
  • Home
  • Organizations
  • Researchers
  • Research Outputs
  • Explore by
    • Organizations
    • Researchers
    • Research Outputs
  • Academic & Publications
  • Sign in
  • 中文
  • English
  1. NTU Scholars
  2. 醫學院
  3. 腫瘤醫學研究所
Please use this identifier to cite or link to this item: https://scholars.lib.ntu.edu.tw/handle/123456789/495155
Title: Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer
Authors: CHIH-HSIN YANG 
PAN-CHYR YANG 
Wang L.S.
Lee Y.C.
Chang C.J.
Lui L.T.
Yen S.H.
CHIUN HSU 
ANN-LII CHENG 
Liu M.Y.
Chiang S.C.
Chen Y.M.
KWEN-TAY LUH 
Huang M.H.
Yang P.-C.
Perng R.-P.
Issue Date: 2002
Journal Volume: 86
Journal Issue: 2
Start page/Pages: 190-195
Source: British Journal of Cancer
Abstract: 
The role of new cytotoxic agents like gemcitabine has not yet been proven in the neoadjuvant settings. We designed a phase II study to test the feasibility of using gemcitabine and cisplatin before local treatment for stage III non-small cell lung cancer patients. Patients received three cycles of induction chemotherapy of gemcitabine (1000 mg m-2, days 1, 8, 15) and cisplatin (90 mg m-2, day 15) every 4 weeks before evaluation for operability. Operable patients underwent radical resection. Inoperable patients and patients who had incomplete resection received concurrent chemoradiotherapy with daily low dose cisplatin. All patients who did not progress after local treatment received three more cycles of adjuvant chemotherapy of gemcitabine and cisplatin. Fifty-two patients received induction treatment. Two patients had complete response and 31 patients had partial response (response rate 63.5%) after induction chemotherapy. Thirty-six patients (69%) were operable. Eighteen patients (35%) had their tumours completely resected. Two patients had pathological complete response. Median overall survival was 19.1 months, projected 1-year survival was 66% and 2-year survival was 34%. Three cycles of gemcitabine and cisplatin is effective and can be used as induction treatment before surgery for locally advanced non-small cell lung cancer patients. ? 2002 The Cancer Research Campaign.
URI: https://www.scopus.com/inward/record.uri?eid=2-s2.0-18244403565&doi=10.1038%2fsj.bjc.6600044&partnerID=40&md5=74ed2c7f42aec07ff943e735218f96cf
https://scholars.lib.ntu.edu.tw/handle/123456789/495155
ISSN: 0007-0920
DOI: 10.1038/sj.bjc.6600044
SDG/Keyword: cisplatin; cytotoxic agent; gemcitabine; adjuvant chemotherapy; adult; aged; alopecia; anemia; article; cancer radiotherapy; cancer staging; cancer surgery; clinical trial; diarrhea; drug efficacy; female; fever; human; human tissue; inoperable cancer; leukopenia; lung non small cell cancer; major clinical study; male; mucosa inflammation; nausea; neutropenia; pathology; phase 2 clinical trial; preoperative treatment; priority journal; survival rate; thrombocytopenia; treatment outcome; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Survival Analysis; Treatment Outcome
[SDGs]SDG3
Appears in Collections:腫瘤醫學研究所

Show full item record

SCOPUSTM   
Citations

24
checked on Mar 20, 2023

WEB OF SCIENCETM
Citations

20
checked on Mar 19, 2023

Page view(s)

18
checked on Mar 19, 2023

Google ScholarTM

Check

Altmetric

Altmetric

Related Items in TAIR


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

臺大位居世界頂尖大學之列,為永久珍藏及向國際展現本校豐碩的研究成果及學術能量,圖書館整合機構典藏(NTUR)與學術庫(AH)不同功能平台,成為臺大學術典藏NTU scholars。期能整合研究能量、促進交流合作、保存學術產出、推廣研究成果。

To permanently archive and promote researcher profiles and scholarly works, Library integrates the services of “NTU Repository” with “Academic Hub” to form NTU Scholars.

總館學科館員 (Main Library)
醫學圖書館學科館員 (Medical Library)
社會科學院辜振甫紀念圖書館學科館員 (Social Sciences Library)

開放取用是從使用者角度提升資訊取用性的社會運動,應用在學術研究上是透過將研究著作公開供使用者自由取閱,以促進學術傳播及因應期刊訂購費用逐年攀升。同時可加速研究發展、提升研究影響力,NTU Scholars即為本校的開放取用典藏(OA Archive)平台。(點選深入了解OA)

  • 請確認所上傳的全文是原創的內容,若該文件包含部分內容的版權非匯入者所有,或由第三方贊助與合作完成,請確認該版權所有者及第三方同意提供此授權。
    Please represent that the submission is your original work, and that you have the right to grant the rights to upload.
  • 若欲上傳已出版的全文電子檔,可使用Sherpa Romeo網站查詢,以確認出版單位之版權政策。
    Please use Sherpa Romeo to find a summary of permissions that are normally given as part of each publisher's copyright transfer agreement.
  • 網站簡介 (Quickstart Guide)
  • 使用手冊 (Instruction Manual)
  • 線上預約服務 (Booking Service)
  • 方案一:臺灣大學計算機中心帳號登入
    (With C&INC Email Account)
  • 方案二:ORCID帳號登入 (With ORCID)
  • 方案一:定期更新ORCID者,以ID匯入 (Search for identifier (ORCID))
  • 方案二:自行建檔 (Default mode Submission)
  • 方案三:學科館員協助匯入 (Email worklist to subject librarians)
Build with DSpace-CRIS - Extension maintained and optimized by Logo 4SCIENCE Feedback